Warning letter · FDA Warning Letters

Crystal Clear Supplements: FDA Warning Letter 620285 (Feb 4, 2022)

Agency action: Feb 4, 2022Record ID: fda_warning_-36e29f4fb268eaa3
View official source ↗

What happened

Original notice title

Crystal Clear Supplements MARCS-CMS 620285, February 04, 2022

From the archived source record

The claims on your website, social media websites and product packaging establish that your products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, FDA has warned consumers about products containing tianeptine, which is used as a prescription drug in some European, Asian, and Latin American countries but is not an FDA-approved drug in the United States. Noopept is fast acting and provides a cognitive boost. . . has mild anxiolytic effects. . . . neuroprotective, has antioxidant abilities, and aids in blocking neurotoxicity. . . treat Alzheimer’s disease, meaning it has positive effects on memory and learning abilities.” “L-Theanine Capsules” From the product webpage at [see original source] • “Tags: anxiety, . . . memory, mental performance, natural depression remedy” • “Medical studies indicate that L-theanine is neuroprotective and can improve symptoms of depression, anxiety, insomnia, and cognitive impairment. . . . The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. You should take prompt action to address the violations cited in this letter. Failure to promptly address these violations may result in enforcement action without further notice, including, without limitation, seizure and/or injunction. Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps that you have taken to address these violations.

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
No closeout listed in FDA table
Source checked
Jul 16, 2026
Record revision
a1cf9b729a1f

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
Tianeptine Sodium Powder; Tianeptine Sulfate Powder; PEA Capsules; Phenibut Capsules; Synephrine Powder; Noopept Powder; L-Theanine Capsules; Lutein Capsules; Stress Reducing Mood Boosting; MOOD ELEVATION -ENHANCED SLEEP- HEIGHTENED FOCUS; 301(d) of the Federal Food; and Cosmetic Act (the FD&C Act); packaging: • “Stress Reducing Mood Boosting” From the product webpages at https://www
Company
Crystal Clear Supplements
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.